Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy

International Journal of Gynecological Cancer

Volumn 20, Issue 3, 2010, Pages 379-384

  Uzan, Catherine ^a   Vincens, Etienne ^a   Balleyguier, Corinne ^a   Gouy, Sebastien ^a   Pautier, Patricia ^a   Duvillard, Pierre ^a   Haie Meder, Christine ^a   Morice, Philippe ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cervical cancer; Chemoradiation; Completion surgery; Incomplete resection; Residual disease

Indexed keywords

CISPLATIN; TOPOTECAN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LAPAROTOMY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; PELVIS EXENTERATION; PERITONITIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR LOCALIZATION; URINE RETENTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PARA-AORTIC BODIES; PELVIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77952124927     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181d2c234     Document Type: Article

References (31)

1. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802-5812.
2. Morice P, Uzan C, Zafrani Y, et al. The role of surgery after chemoradiation therapy and brachytherapy for stage IB2/II cervical cancer. Gynecol Oncol. 2007;107: S122-S124.
3. International Commission on Radiation Units and Measurements. Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology. ICRU; 1985. Report no. 38. Available at: http://www.icru.org/index. php?option=com-content&task=view&id=86. Accessed February 18, 2010.
4. Delpech Y, Haie-Meder C, Rey A, et al. Para-aortic involvement in stage IB 2/II cervical carcinoma confined radiologically to the pelvic cavity treated using pelvic radiotherapy and concomitant chemotherapy. Ann Surg Oncol. 2007;14:3223-3231.
5. Keys HM, Bundy BN, Stehman FB, et al. Gynecologic Oncology Group. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol. 2003;89:343-353.
6. Darus CJ, Callahan MB, Nguyen QN, et al. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer. 2008;18:730-735.
7. Azria E, Morice P, Haie-Meder C, et al. Results of hysterectomy in patients with bulky residual disease at the end of chemoradiation therapy for stage IB2/II cervical carcinoma. Ann Surg Oncol. 2005;12:332-337.
8. Houvenaeghel G, Lelievre L, Rigouard AL, et al. Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Gynecol Oncol. 2006;102:74-79.
9. Houvenaeghel G, Lelievre L, Gonzague-Casabianca L, et al. Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol Oncol. 2006;100:338-343.
10. Distefano M, Fagotti A, Ferrandina G, et al. Preoperative chemoradiotherapy in locally advanced cervical cancer: long term outcome and complications. Gynecol Oncol. 2005;99: S166YS170.
11. Classe JM, Rauch P, Rodier JF, et al. Surgery after concurrent chemoradiatherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: Results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centres de Lutte Contre le Cancer). Gynecol Oncol. 2006;102:523-529.
12. Houvenaeghel G, Lelievre L, Butarelli M, et al. Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma. Eur J Surg Oncol. 2007;33:498-503.
13. Subak LL, Hricak H, Powell CB, et al. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol. 1995;6:43-50.
14. Hricak H, Lacey CG, Sandles LG, et al. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology. 1988;166:623-632.
15. Hawnaur JM, Johnson RJ, Buckley CH, et al. Staging, volume estimation and assessment of nodal status in carcinoma of the cervix: comparison of magnetic resonance imaging with surgical findings. Clin Radiol. 1994;49:443-452.
16. Yamashita Y, Takahashi M, Sawada T, et al. Carcinoma of the cervix: dynamic MR imaging. Radiology. 2002;182:643-648.
17. Bipat S, Glas AS, Van der Velden J, et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol. 2003;91:59-66.
18. Scheidler J, Heuck AF. Imaging of cancer of the cervix. Radiol Clin North Am. 2002;40:577-590.
19. Hatano K, Sekiya Y, Araki H, et al. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiation Oncol Biol Phys. 1999;45:639-644.
20. Vincens E, Balleyguier C, Rey A, et al. Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy: correlation of radiologic findings with surgicopathologic results. Cancer. 2008;113:2158-2165.
21. Nam H, Park W, Huh SJ, et al. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol. 2007;107:320-325
22. Mayr NA, Taoka T, Yuh WTC, et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002;52:14-22.
23. Nijhuis ER, van der ZEE AG, in't Hout BA, et al. Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys. 2006;66:699-705.
24. Ohara K, Tanaka YO, Tsunoda H, et al. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol. 2002;100:781-787.
25. Ngan HYS, Chan SYW, Wong LC, et al. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol. 1990;37:260-263.
26. Yoon SM, Shin KH, Kim JY, et al. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy. Int J Gynecol Cancer. 2007;17:872-878.
27. Naganawa S, Sato C, Kumada H, et al. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur Radiol. 2005;15:71-78.
28. Lin LL, Yang Z, Miller TR, et al. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int J Radiat Oncol Biol Phys. 2006;65:177-181.
29. Liu Y, Bai R, Sun H, et al. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol. 2009;64:1067-1074.
30. Bonvalot S, Muret J, Debaere T. Pelvic perfusion for locally advanced tumors. Bull Cancer. 2009;96:103-109.
31. Snoeck R. Papillomavirus and treatment. Antiviral Res. 2006;71:181-191.